Neda Amini1, Georgios Antonios Margonis1, Yuhree Kim1, Thuy B Tran2, Lauren M Postlewait3, Shishir K Maithel3, Tracy S Wang4, Douglas B Evans4, Ioannis Hatzaras5, Rivfka Shenoy5, John E Phay6, Kara Keplinger6, Ryan C Fields7, Linda X Jin7, Sharon M Weber8, Ahmed Salem8, Jason K Sicklick9, Shady Gad9, Adam C Yopp10, John C Mansour10, Quan-Yang Duh11, Natalie Seiser11, Carmen C Solorzano12, Colleen M Kiernan12, Konstantinos I Votanopoulos13, Edward A Levine13, George A Poultsides2, Timothy M Pawlik14. 1. Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA. 3. Department of Surgery, Emory University, Atlanta, GA, USA. 4. Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA. 5. Department of Surgery, New York University School of Medicine, New York, NY, USA. 6. Department of Surgery, The Ohio State University, Columbus, OH, USA. 7. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA. 8. Department of General Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 9. Department of Surgery, University of California San Diego, San Diego, CA, USA. 10. Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA. 11. Department of Surgery, University of California San Francisco, San Francisco, CA, USA. 12. Department of Surgery, Vanderbilt University, Nashville, TN, USA. 13. Department of Surgery, Wake Forest School of Medicine, Winston-Salem, NC, USA. 14. Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. tpawlik1@jhmi.edu.
Abstract
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy. The aim of this study was to determine the incidence and patterns of recurrence after curative-intent surgery for ACC. METHODS: Patients who underwent curative-intent resection for ACC between 1993 and 2014 were identified from 13 academic institutions participating in the United States ACC study group. Patients with metastasis or an R2 margin were excluded. Patterns and rates of recurrence were determined and classified as locoregional and distant recurrence. RESULTS: A total of 180 patients with a median age of 52 years (interquartile range 43-61) were identified. Most patients underwent open surgery (n = 111, 64.5 %) and had an R0 resection margin (n = 117, 75.0 %). At last follow-up, 116 patients (64.4 %) had experienced recurrence (locoregional only, n = 41, 36.3 %; distant only, n = 51, 45.1 %; locoregional and distant, n = 21, 18.6 %). Median time to recurrence was 18.8 months. Several factors were associated with locoregional recurrence, including left-sided ACC location (odds ratio [OR] 2.71, 95 % confidence interval [CI] 1.06-6.89) and T3/T4 disease (reference T1/T2, OR 3.04, 95 % CI 1.19-7.80) (both p < 0.05). Distant recurrence was associated with larger tumor size (OR 1.11, 95 % CI 1.01-1.24) and T3/T4 disease (reference T1/T2, OR 5.23, 95 % CI 1.70-16.10) (both p < 0.05). Patients with combined locoregional and distant recurrence had worse survival (3- and 5-year survival: 39.5, 19.7 %) versus patients with distant-only (3- and 5-year survival 55.1, 43.3 %) or locoregional-only recurrence (3- and 5-year survival 81.4, 64.1 %) (p = 0.01). CONCLUSIONS: Nearly two-thirds of patients experienced disease recurrence after resection of ACC. Although a subset of patients experienced recurrence with locoregional disease only, many patients experienced recurrence with distant disease as a component of recurrence and had a poor prognosis.
BACKGROUND:Adrenocortical carcinoma (ACC) is a rare malignancy. The aim of this study was to determine the incidence and patterns of recurrence after curative-intent surgery for ACC. METHODS:Patients who underwent curative-intent resection for ACC between 1993 and 2014 were identified from 13 academic institutions participating in the United States ACC study group. Patients with metastasis or an R2 margin were excluded. Patterns and rates of recurrence were determined and classified as locoregional and distant recurrence. RESULTS: A total of 180 patients with a median age of 52 years (interquartile range 43-61) were identified. Most patients underwent open surgery (n = 111, 64.5 %) and had an R0 resection margin (n = 117, 75.0 %). At last follow-up, 116 patients (64.4 %) had experienced recurrence (locoregional only, n = 41, 36.3 %; distant only, n = 51, 45.1 %; locoregional and distant, n = 21, 18.6 %). Median time to recurrence was 18.8 months. Several factors were associated with locoregional recurrence, including left-sided ACC location (odds ratio [OR] 2.71, 95 % confidence interval [CI] 1.06-6.89) and T3/T4 disease (reference T1/T2, OR 3.04, 95 % CI 1.19-7.80) (both p < 0.05). Distant recurrence was associated with larger tumor size (OR 1.11, 95 % CI 1.01-1.24) and T3/T4 disease (reference T1/T2, OR 5.23, 95 % CI 1.70-16.10) (both p < 0.05). Patients with combined locoregional and distant recurrence had worse survival (3- and 5-year survival: 39.5, 19.7 %) versus patients with distant-only (3- and 5-year survival 55.1, 43.3 %) or locoregional-only recurrence (3- and 5-year survival 81.4, 64.1 %) (p = 0.01). CONCLUSIONS: Nearly two-thirds of patients experienced disease recurrence after resection of ACC. Although a subset of patients experienced recurrence with locoregional disease only, many patients experienced recurrence with distant disease as a component of recurrence and had a poor prognosis.
Authors: Ricardo J Gonzalez; Suzanne Shapiro; Nicholas Sarlis; Rena Vassilopoulou-Sellin; Nancy D Perrier; Douglas B Evans; Jeffrey E Lee Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: Aaron Sabolch; Tobias Else; Kent A Griffith; Edgar Ben-Josef; Andrew Williams; Barbra S Miller; Francis Worden; Gary D Hammer; Shruti Jolly Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-05 Impact factor: 7.038
Authors: David Brix; Bruno Allolio; Wiebke Fenske; Ayman Agha; Henning Dralle; Christian Jurowich; Peter Langer; Thomas Mussack; Christoph Nies; Hubertus Riedmiller; Martin Spahn; Dirk Weismann; Stefanie Hahner; Martin Fassnacht Journal: Eur Urol Date: 2010-06-22 Impact factor: 20.096
Authors: M L Kendrick; R Lloyd; L Erickson; D R Farley; C S Grant; G B Thompson; C Rowland; W F Young; J A van Heerden Journal: Arch Surg Date: 2001-05
Authors: Sherita H Golden; Karen A Robinson; Ian Saldanha; Blair Anton; Paul W Ladenson Journal: J Clin Endocrinol Metab Date: 2009-06 Impact factor: 5.958
Authors: Thuy B Tran; Shishir K Maithel; Timothy M Pawlik; Tracy S Wang; Ioannis Hatzaras; John E Phay; Ryan C Fields; Sharon M Weber; Jason K Sicklick; Adam C Yopp; Quan-Yang Duh; Carmen C Solorzano; Konstantinos I Votanopoulos; George A Poultsides Journal: J Am Coll Surg Date: 2016-09-13 Impact factor: 6.113
Authors: Paula Marincola Smith; Colleen M Kiernan; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Jason Prescott; Timothy Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivka Shenoy; John Phay; Lawrence A Shirley; Ryan C Fields; Linda Jin; Sharon Weber; Ahmed Salem; Jason Sicklick; Shady Gad; Adam Yopp; John Mansour; Quan-Yang Duh; Natalie Seiser; Konstantinos Votanopoulos; Edward A Levine; George Poultsides; Carmen C Solórzano Journal: Ann Surg Oncol Date: 2018-06-04 Impact factor: 5.344
Authors: Jülide Durmuşoğlu; Henri J L M Timmers; Pepijn van Houten; Johan F Langenhuijsen; Ad R M M Hermus; Annenienke C van de Ven Journal: Endocr Connect Date: 2020-10 Impact factor: 3.335